Oxford BioTherapeutics (OBT) is focused on the development of targeted antibody-based medicines for oncology. OBT’s strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database. Through its alliances with the world leaders in antibody development (Medarex, Biosite, Amgen and GSK), OBT is in an unrivalled position to convert its novel targets into an exciting pipeline of first-in-class therapeutics for the treatment of cancer. OBT’s pipeline will deliver cost-effective medicines to fulfill the major unmet medical need of cancer patients.